<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   COVID-19: Care of adult patients with systemic rheumatic disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       COVID-19: Care of adult patients with systemic rheumatic disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        COVID-19: Care of adult patients with systemic rheumatic disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sindhu R Johnson, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth G Saag, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alfred HJ Kim, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            E William St Clair, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don L Goldenberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 23, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3110991359">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the end of 2019, a novel coronavirus that was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. By 2020, infection with this virus led to a pandemic that has spread throughout most countries of the world. The illness caused by this virus, which has been termed coronavirus disease 2019 (COVID-19), primarily manifests as a lung infection with symptoms ranging from those of a mild upper respiratory infection to severe pneumonia, acute respiratory distress syndrome, and death.
        </p>
        <p>
         Severe illness can occur in previously healthy individuals, but also in patients with underlying medical conditions, including patients with systemic rheumatic diseases. This topic will discuss the care of patients with systemic rheumatic diseases during the COVID-19 pandemic. Other important aspects of COVID-19 infection are reviewed in detail separately; please refer to our
         <a class="external" href="/landing/covid19" target="_blank">
          COVID-19 homepage
         </a>
         to view the complete list of UpToDate COVID-19 topics.
        </p>
        <p class="headingAnchor" id="H1396930599">
         <span class="h1">
          RISK OF COVID-19 INFECTION
         </span>
        </p>
        <p class="headingAnchor" id="H508097017">
         <span class="h2">
          Disease- and comorbidity-related risks
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of a rheumatologic disease alone may be associated with an increased risk for developing COVID-19 with more adverse outcomes, although the evidence is mixed and likely related to the heterogeneity of these disorders and their therapies [
         <a href="#rid1">
          1-12
         </a>
         ]. One cohort study found that the risk of severe COVID-19 was similar among patients with rheumatologic diseases compared with matched controls, although there was a trend towards more severe COVID-19 among the subset of patients with connective tissue disease (1.82, 95% CI 1.00-3.30), unlike those with inflammatory arthritis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         There are limited data specifically regarding patients with systemic lupus erythematosus (SLE) and COVID-19. It is uncertain whether patients with SLE are at any increased risk of COVID-19. In one large cohort of unvaccinated patients with SLE in New York City, 4 percent developed symptomatic COVID-19, while the estimated general population prevalence of infection was 2 percent [
         <a href="#rid13">
          13
         </a>
         ]. Baseline use of immunosuppressive drugs did not appear to affect the severity of infection. In a registry study of 1606 patients with SLE, worse outcomes were associated with older age, male sex,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         use, comorbidities such as kidney and cardiovascular disease, and increased lupus disease activity [
         <a href="#rid14">
          14
         </a>
         ]. Compared with White individuals who have SLE, Black and Hispanic patients with SLE have been shown to experience more severe outcomes, similar to what is observed in the general population [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Gout may be associated with a higher risk of COVID-19. In a study of 1,390,953 patients who have received a SARS-CoV-2 vaccine, gout was associated with an increased risk of breakthrough infections (partially adjusted HR 1.24, 95% CI 1.19-1.30) and hospitalization (adjusted hazard ratio [HR] 1.30, 95% CI 1.10-1.53) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Patients with various rheumatologic diseases have a higher prevalence of several comorbidities such as advanced age, chronic pulmonary and kidney disease, heart disease, hypertension, obesity, and diabetes [
         <a href="#rid17">
          17-25
         </a>
         ], which in turn are risk factors for severe illness with COVID-19. Findings from observational studies (prior to the availability of vaccines) suggest that comorbidities in patients with rheumatologic diseases contribute to an increased risk of more severe COVID-19 [
         <a href="#rid1">
          1,3-7,10
         </a>
         ]. In a case series of 600 patients with rheumatologic diseases and COVID-19, a multivariable-adjusted analysis showed hospitalized cases in comparison with nonhospitalized cases had more comorbidities, including hypertension (45 versus 23 percent), lung disease (30 versus 14 percent), diabetes (17 versus 7 percent), cardiovascular disease (14 versus 7 percent), and chronic renal insufficiency/end-stage kidney disease (12 versus 2 percent) [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features", section on 'Risk factors for severe illness'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features", section on 'Increasing age'
         </a>
         .)
        </p>
        <p>
         There is limited high-quality evidence regarding the incremental risk for hospitalization due to COVID-19 infection attributable to an established rheumatologic disease [
         <a href="#rid8">
          8,10,26-30
         </a>
         ]. In a large cohort study of United States veterans conducted prior to the availability of COVID-19 vaccines, a diagnosis of rheumatoid arthritis was associated with an increased risk of COVID-19 and COVID-19-related hospitalization or death compared with patients without rheumatoid arthritis (HR 1.25, 95% CI 1.13-1.39, and HR 1.35, 95% CI 1.10-1.66, respectively) [
         <a href="#rid8">
          8
         </a>
         ]. Factors associated with these adverse outcomes included disease-modifying antirheumatic drug (DMARD) and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         use, being a Black or Hispanic American, and several chronic conditions. In addition, a nationwide cohort study from Demark including over 58,000 patients with systemic rheumatic diseases, also prior to the availability of COVID-19 vaccines, found that patients with systemic rheumatic diseases were more likely to be hospitalized compared with the general population (HR 1.46, 95% CI 1.15-1.86) [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Certain laboratory abnormalities have been associated with poor outcomes in patients with COVID-19, such as lymphopenia (particularly low CD4+ T cells) and elevated levels of C-reactive protein, interleukin (IL) 6, and creatine kinase (see
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features", section on 'Risk factors for severe illness'
         </a>
         ); these abnormalities result from the infection and the immune response to the infection. It is unknown whether such abnormalities, if pre-existing due to another disorder (eg, a systemic rheumatic disease), have any impact on disease outcome.
        </p>
        <p class="headingAnchor" id="H4275728806">
         <span class="h2">
          Risks associated with rheumatologic disease therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatments for rheumatologic disease impact the risk of COVID-19 infection by impairing the immunologic response to the virus as well as to protective vaccines [
         <a href="#rid31">
          31-37
         </a>
         ]. Both
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX) and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         have been associated with increased risk of repeat COVID-19 infection in patients with rheumatic diseases [
         <a href="#rid38">
          38
         </a>
         ]. Treatment with B cell-depleting agents such as rituximab are a particular concern because they impair humoral responses to vaccination. (See
         <a class="local">
          'Coordinating vaccine administration with immunosuppressive therapy'
         </a>
         below.)
        </p>
        <p>
         Therapies for rheumatologic disease may also lead to worse outcomes for patients once infected with SARS-CoV-2. Although the data are mixed, available large cohort studies suggest that B-cell depletion with agents such as
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and certain other immunosuppressive agents, particularly
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (CYC) and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , appear to be associated with higher risk of worse outcomes for COVID-19 [
         <a href="#rid3">
          3,25-27,39-52
         </a>
         ]. Studies on specific agents include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         – Several studies have suggested that patients who develop COVID-19 infection and are treated with rituximab, including patients with rheumatoid arthritis, are at increased risk of a more prolonged disease course, severe disease, and/or worse outcomes [
         <a href="#rid11">
          11,25,47,53-56
         </a>
         ]. Therefore, administration of a subsequent dose of rituximab should be delayed, or the patient should be transitioned to another immunosuppressive agent, whenever possible [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic glucocorticoids – Although glucocorticoids may be a useful intervention for severe COVID-19 (see
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'
         </a>
         ), limited observational data have raised the question of whether glucocorticoid therapy may also be associated with increased susceptibility to more severe disease in both rheumatologic [
         <a href="#rid3">
          3,25,58
         </a>
         ] and inflammatory bowel disease. (See
         <a class="medical medical_review" href="/z/d/html/127965.html" rel="external">
          "COVID-19: Issues related to gastrointestinal disease in adults", section on 'Adjusting IBD medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The lack of benefit of HCQ therapy for treatment of COVID-19 infection is described separately. (See
         <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">
          "COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies that we do not recommend'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3588246092">
         <span class="h1">
          CLINICAL MANIFESTATIONS AND DIAGNOSTIC CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2183859772">
         <span class="h2">
          Clinical presentation of the infection in patients with rheumatologic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features of COVID-19 among patients with systemic rheumatic diseases are variable and are not known to be different than patients without these underlying diseases. There are insufficient data from reported cases to determine whether the type of rheumatologic disease or the intensity of immunosuppressive therapy influences the clinical presentation of COVID-19 in this population (see
         <a class="local">
          'Disease registries'
         </a>
         below). However, it is possible that some features of rheumatologic disease may be difficult to distinguish from those of COVID-19. (See
         <a class="local">
          'Features of rheumatologic disease that can mimic or be mimicked by COVID-19'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H303444211">
         <span class="h2">
          Features of rheumatologic disease that can mimic or be mimicked by COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of rheumatologic diseases may have clinical features that can mimic or be mimicked by COVID-19, such as fever, malaise, myalgias, and fatigue. For patients who carry an existing diagnosis of a rheumatologic disease, the clinician may need to distinguish a disease flare from possible COVID-19 infection, and a high level of suspicion for this infection should be maintained when and where COVID-19 may be prevalent. The approach to testing for COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
         Specific examples of such conditions include diseases that can manifest with fever (eg, systemic lupus erythematosus [SLE]); headache (eg, giant cell arteritis [GCA] [
         <a href="#rid59">
          59
         </a>
         ]); gastrointestinal symptoms (eg, spondyloarthritis, systemic sclerosis [SSc], SLE, and Behçet syndrome); dyspnea (eg, interstitial pulmonary disease due to rheumatoid arthritis, SSc, or SLE); stroke (eg, antiphospholipid syndrome [APS]); pernio- or chilblain-like lesions, sometimes called "COVID toes" (eg, chilblain lupus erythematosus); and a Kawasaki-like multisystem inflammatory syndrome in children (MIS-C, also referred to as pediatric multisystem inflammatory syndrome [PMIS]). Patients with severe COVID-19 can also develop cutaneous vasculitis-like lesions and systemic arterial and venous thromboemboli, including cryptogenic strokes and other vasculopathy features [
         <a href="#rid60">
          60,61
         </a>
         ]. Additionally, some patients experience a more prolonged recovery from COVID-19 infection, with persistent symptoms including fatigue and dyspnea. (See
         <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">
          "COVID-19: Hypercoagulability", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127978.html" rel="external">
          "COVID-19: Cutaneous manifestations and issues related to dermatologic care", section on 'Cutaneous manifestations of COVID-19'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129312.html" rel="external">
          "COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID")", section on 'Persistent symptoms'
         </a>
         .)
        </p>
        <p>
         In addition, laboratory abnormalities such as an elevated erythrocyte sedimentation rate, C-reactive protein levels, ferritin, interleukin (IL) 6, and creatine kinase levels can be seen in both COVID-19 and in association with various rheumatologic diseases.
        </p>
        <p>
         Medications used to treat rheumatologic disease may also cause adverse effects that can mimic clinical manifestations of COVID-19 (eg,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         [SSZ], which may cause gastrointestinal symptoms, and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [MTX], which may cause pulmonary abnormalities).
        </p>
        <p>
         Referral for rheumatologic evaluation may be appropriate in patients with known or suspected COVID-19 who do not have an established rheumatologic disease diagnosis yet have additional clinical features concerning for rheumatologic disease (eg, findings suggestive of synovitis or serologies characteristic of autoimmune rheumatic disease).
        </p>
        <p class="headingAnchor" id="H1119802728">
         <span class="h2">
          COVID-19 as a risk factor for rheumatologic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         New-onset rheumatologic disease appears to be uncommon following COVID-19, but cases of incident systemic rheumatic disease are increasingly described; among them are inflammatory arthritis, GCA, inflammatory myopathy, APS, and Sjögren's disease [
         <a href="#rid62">
          62,63
         </a>
         ]. However, it remains uncertain whether reported cases are causally related to the viral infection.
        </p>
        <p>
         Other case reports of possible virus-associated new-onset systemic rheumatic diseases include reactive arthritis [
         <a href="#rid64">
          64,65
         </a>
         ]; crystal-induced arthritis [
         <a href="#rid66">
          66
         </a>
         ]; SSc [
         <a href="#rid67">
          67
         </a>
         ], antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [
         <a href="#rid68">
          68,69
         </a>
         ]; adult-onset Still's disease [
         <a href="#rid70">
          70
         </a>
         ]; small vessel cardiac vasculitis and endotheliitis [
         <a href="#rid71">
          71
         </a>
         ]; and immunoglobulin (Ig) A vasculitis [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H252402466">
         <span class="h2">
          Multisystem inflammatory syndrome in adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, a multisystem inflammatory syndrome (MIS) similar to Kawasaki disease has been seen that occurs almost exclusively in children (see
         <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"
         </a>
         ); though cases have also been reported in adults (MIS-A) [
         <a href="#rid73">
          73-79
         </a>
         ]. A
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fmis-a%2Fhcp.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLKWuDotKgoiMLjr9apdoqys98%2FweMX5uFmSB8qW%2B0MeO&amp;TOPIC_ID=127933" target="_blank">
          case definition for MIS-A
         </a>
         from the Centers for Disease Control and Prevention (CDC) has been established [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         An analysis from the CDC of 27 reported cases of MIS-A noted that it is characterized by markedly elevated inflammatory markers and multiorgan dysfunction, particularly cardiac dysfunction, but without severe respiratory illness [
         <a href="#rid74">
          74
         </a>
         ]. Other features have included gastrointestinal, dermatologic, and neurologic symptoms. Exposure to SARS-CoV-2 was documented by either concurrent positive polymerase chain reaction (PCR) test results (approximately two-thirds of patients) or antibody assays indicating recent infection. Antibody testing to confirm previous SARS-CoV-2 infection can be important in identifying MIS-A among those with compatible signs and symptoms, as these patients might not have positive SARS-CoV-2 PCR or antigen test results at the time of presentation with this illness. Optimal treatment strategies have not been determined, but these patients have generally been managed very similarly to children with MIS-C. (See
         <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome"
         </a>
         .)
        </p>
        <p>
         In a subsequent systematic review of reported cases of MIS-A involving 221 patients, the median onset of disease was approximately 4 weeks after acute COVID-19 infection [
         <a href="#rid79">
          79
         </a>
         ]. The major disease manifestations included fever, hypotension, cardiac dysfunction, shortness of breath, and diarrhea. The majority of patients were admitted to the intensive care unit (57 percent), and 7 percent died.
        </p>
        <p>
         MIS-A/MIS-C may be difficult to distinguish from biphasic acute COVID-19 and sequelae of acute SARS-CoV-2 infection; however, there are some clinical characteristics that may help distinguish acute severe COVID-19 and MIS-C/MIS-A. As an example, children with MIS-C are commonly between the ages of 6 and 12, are non-Hispanic Black, and have severe cardiovascular or mucocutaneous involvement and severe inflammation [
         <a href="#rid81">
          81
         </a>
         ]. It is uncertain whether these distinctions also apply to MIS-A. (See
         <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis", section on 'Differentiating MIS-C and acute COVID-19'
         </a>
         .)
        </p>
        <p>
         Notably, the incidence of MIS-C correlates with the main circulating variant of SARS-CoV-2. In the Paediatric Active Enhanced Disease Surveillance (PAEDS) network from Australia, the pre-Delta rate was 13 cases per 10,000, which decreased to 5 per 10,000 during Delta and 0.8 per 10,000 during Omicron [
         <a href="#rid82">
          82
         </a>
         ]. Similar reductions in incidence have been observed in Israel [
         <a href="#rid83">
          83
         </a>
         ] and Denmark [
         <a href="#rid84">
          84
         </a>
         ]. It remains unclear whether this represents an attenuation of certain variants to trigger hyperinflammation or reflects increased acquired immunity (whether through infection or vaccination), although vaccination has been associated with reductions in MIS-C incidence [
         <a href="#rid85">
          85-87
         </a>
         ].
        </p>
        <p>
         For individuals who had SARS-CoV-2 infection complicated by MIS, there are theoretical concerns regarding immune dysregulation that could potentially be triggered by the SARS-CoV-2 vaccine that are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'History of SARS-CoV-2 infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3227476558">
         <span class="h1">
          MANAGEMENT OF PATIENTS WITH KNOWN OR SUSPECTED SARS-CoV-2 EXPOSURE OR INFECTION
         </span>
        </p>
        <p class="headingAnchor" id="H2945944968">
         <span class="h2">
          Medication management in patients following exposure
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatologic disease medications
         </strong>
         – Adjustments to medication regimens in patients thought to be recently exposed to the SARS-CoV-2 virus should be individualized, with considerations regarding vaccination status, suspected or known individual's vaccine response, patient's immunosuppressive regimen (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         use) and other risk factors, and access to COVID-19-specific therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vaccinated individuals
         </strong>
         – Although the assessment should be individualized, patients effectively vaccinated may generally be able to continue immunosuppressive therapy following exposure. By contrast, a patient who is due for a subsequent dose of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         but lacks evidence of an antibody response to vaccination may benefit from a delay in the scheduled infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Unvaccinated individuals
         </strong>
         – Our approach to medication management following exposure in unvaccinated individuals is largely based upon expert opinion and extrapolation from the management of patients taking these medications who have developed other infections and is consistent with the management practices recommended by the American College of Rheumatology (ACR) [
         <a href="#rid88">
          88
         </a>
         ], as well as being generally similar to other guidelines [
         <a href="#rid57">
          57,89-91
         </a>
         ]. High-quality evidence regarding the effects of stopping or maintaining medications for systemic rheumatic diseases in the setting of SARS-CoV-2 exposure is lacking.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Our general approach to medication management of unvaccinated individuals after a significant exposure is as follows [
         <a href="#rid88">
          88
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          Sulfasalazine
         </a>
         (SSZ), nonsteroidal antiinflammatory drugs (NSAIDs), and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         (HCQ)/
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         (CQ) may be continued. NSAID use would not differ from patients without exposure to SARS-CoV-2, consistent with most international and specialty guidelines [
         <a href="#rid88">
          88,92-94
         </a>
         ]. There is a lack of scientific evidence for any novel increased risk associated with NSAID use in patients with COVID-19, and several reports support their safety [
         <a href="#rid95">
          95,96
         </a>
         ]. SSZ can be continued given the relatively low risk of serious infection associated with it [
         <a href="#rid97">
          97,98
         </a>
         ]. However, there are data suggesting uncertainty regarding the safety of SSZ among patients with COVID-19 [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Whether
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX) or
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         (LEF) should be discontinued must be assessed on a case-by-case basis weighing the potential risks of infection and its sequelae against the possible risk of rheumatologic disease flare during the period the drug is held. If the medications have been temporarily held, they can generally be resumed pending a negative test result for COVID-19 or after two weeks of symptom-free observation. Treatment with MTX and LEF is also associated with a relatively low risk of serious infection [
         <a href="#rid99">
          99,100
         </a>
         ], particularly when given as monotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For most patients who are asymptomatic and recently exposed to SARS-CoV-2, we typically stop
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (CYC),
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA),
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , anti-tumor necrosis factor (TNF) agents,
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         , interleukin (IL) 6 receptor inhibitors, and Janus kinase (JAK) inhibitors (eg,
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         ), pending a negative test result for COVID-19 or after two weeks of symptom-free observation (see
         <a class="local">
          'Postinfection management/resumption of therapy'
         </a>
         below). However, these agents may be continued in individual cases, particularly in those for whom an increased risk of disease flare is a substantial concern. In addition, in selected patients, it may be appropriate to continue IL-6 receptor inhibitors as suggested by the ACR guidance [
         <a href="#rid88">
          88
         </a>
         ]. High-quality evidence regarding continuation of the use of IL-6 receptor inhibitors in this setting is lacking. The use of IL-6 inhibitors for the treatment of severe COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Although HCQ is also associated with a low risk of serious infection, reports highlight the potential for cardiotoxicity (particularly QT prolongation and arrhythmias) that could be exacerbated in the setting of COVID-19, during which patients may require use of other QT-prolonging medications [
         <a href="#rid101">
          101
         </a>
         ], which is the rationale for temporarily holding HCQ therapy in patients with known or suspected COVID-19. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Cardiotoxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127551.html" rel="external">
          "COVID-19: Arrhythmias and conduction system disease", section on 'Patients receiving therapies that prolong the QT interval'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         The rationale for temporarily discontinuing the other immunosuppressive drugs, biologic agents, and JAK inhibitors is based upon their associated increased risk of serious infection compared with conventional disease-modifying antirheumatic drugs (DMARDs) [
         <a href="#rid102">
          102,103
         </a>
         ] and the theoretically low likelihood that such a change would trigger a disease flare. However, IL-6 pathway inhibitors, such as
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">
          sarilumab
         </a>
         , or a JAK inhibitor may be effective in hospitalized patients with severe COVID-19 infection for management of an intense inflammatory state similar to a cytokine release syndrome. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Post-exposure prophylaxis
         </strong>
         – The role of post-exposure prophylaxis with monoclonal antibody therapy in individuals at high risk for severe COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'No role for post-exposure prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1530059512">
         <span class="h2">
          Medication management with documented or presumptive COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adjustments to medication regimens in patients with documented or presumptive COVID-19 should be individualized with specific attention to the severity of the infection. Our approach is largely based upon expert opinion and extrapolation from the management of patients on these medications who have developed other infections, and is consistent with the management practices recommended by the ACR [
         <a href="#rid88">
          88
         </a>
         ], as well as being generally similar to other guidelines [
         <a href="#rid57">
          57,89-91
         </a>
         ].
        </p>
        <p>
         Our overall approach to both unvaccinated and vaccinated individuals is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with documented or presumptive COVID-19, we suggest temporarily discontinuing HCQ/CQ, SSZ, MTX, LEF, immunosuppressants (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , AZA), biologic agents (eg, anti-TNF inhibitors, IL-6 receptor inhibitors), and JAK inhibitors during the period of active infection. However, in cases where patients have active or organ-threating rheumatologic disease, continuation of immunosuppressive therapy may be required based upon an individualized assessment. The decision to continue these agents should be made in close consultation with specialists in rheumatology, infectious disease, and critical care who are involved in the management of the patient's acute illnesses. A particular agent may be continued in certain cases when it has proven value for the treatment of certain features of COVID-19 associated with a heightened inflammatory response (eg,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="113315" href="/z/d/drug information/113315.html" rel="external">
          sarilumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Baricitinib and JAK inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The rationale for holding HCQ/CQ is related to its potential for cardiotoxicity, particularly in the context of COVID-19, and is discussed above (see
         <a class="local">
          'Medication management in patients following exposure'
         </a>
         above). For SSZ, the reasoning is mainly related to concerns about potential adverse effects from this agent (eg, gastrointestinal upset, diarrhea, hepatitis, cytopenias, and, rarely, pneumonitis) that could be confused with clinical and laboratory manifestations of COVID-19. Additionally, temporarily holding SSZ for up to two to three weeks would be unlikely to result in significant rheumatologic disease flares.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We discontinue MTX, LEF, immunosuppressants, biologic agents, and JAK inhibitors given our concern for impairing the host defense against COVID-19 and the risk of causing additional infections, although there are no data to confirm or convincingly refute such risk. In addition, the risk of rheumatologic disease flare is likely to be relatively low during a limited period of several weeks. Most infections associated with these medications are bacterial and opportunistic in origin; these risks remain relevant, as a substantial proportion of patients with COVID-19 develop the complication of bacterial pneumonia [
         <a href="#rid104">
          104
         </a>
         ]. Additional risks of treatment with certain biologics and JAK inhibitors include reactivation of viral infections, including herpes zoster [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe respiratory, cardiac, or kidney involvement, NSAIDs should be discontinued as they would be in patients without COVID-19.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients treated with glucocorticoids should maintain the same dose to avoid acute rheumatologic disease flare and the complications of adrenal insufficiency associated with abrupt discontinuation. The use of glucocorticoids, including both systemic (eg, oral) and intraarticular glucocorticoids, should be consistent with best practices employed in patients without COVID-19. As in usual practice, in the setting of a critically ill patient with a swollen joint, the possibility of other infection should be excluded before joint injection, and this approach should be used as sparingly as possible. (See
         <a class="medical medical_review" href="/z/d/html/7986.html" rel="external">
          "Joint aspiration or injection in adults: Technique and indications", section on 'Indications for aspiration or injection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although glucocorticoid therapy increases the risk of infections, abrupt discontinuation of these medications is not feasible or safe in seriously ill patients. To minimize adverse reactions, we treat patients who require glucocorticoids for systemic rheumatic disease with the lowest necessary dose for the shortest period of time. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hospitalized patients with severe COVID-19 infection may receive
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         therapy for cytokine storm. Following cessation of dexamethasone therapy for this indication, patients with rheumatic disease receiving glucocorticoid therapy prior to their hospitalization for COVID-19 infection should generally resume the pre-COVID-19 dose of glucocorticoids. The use of dexamethasone for the treatment of severe COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">
          "COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Patients with oxygen requirement/severe disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3129645571">
         <span class="h2">
          Postinfection management/resumption of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal time to resume immunosuppressive medications after infection with COVID-19 is unknown and has not been subject to empirical study. We base the timing for resumption of antirheumatic drug therapy (including conventional synthetic, biologic, and targeted DMARDs and other immunosuppressive drugs) largely upon the severity and characteristics of the infection in a given patient and the time since exposure to the infection or onset of symptoms. The rheumatologic disease indications and urgency of reinstitution of therapy may also influence timing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic patients without documented infection following suspected exposure
         </strong>
         – For asymptomatic patients without documented infection following suspected exposure, we resume antirheumatic medications once a negative test result has been documented at an appropriate timepoint following the suspected exposure to SARS-CoV-2 or in untested patients, after two weeks of symptom-free observation. (See
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis", section on 'For post-exposure testing'
         </a>
         and
         <a class="local">
          'Medication management in patients following exposure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic patients with positive testing
         </strong>
         – For patients who are and remain asymptomatic but have had a positive reverse transcription polymerase chain reaction (PCR) or antigen test for SARS-CoV-2, we typically resume antirheumatic drug therapy approximately 10 to 17 days after the last date of positive testing. However, the date to resume treatment should be individualized according to vaccination status and/or previous receipt of monoclonal antibodies and other COVID-19-specific therapies. Also, patients with more urgent rheumatologic disease-related indications for therapy might resume therapy earlier in some cases. (See
         <a class="local">
          'Medication management with documented or presumptive COVID-19'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic but uncomplicated COVID-19
         </strong>
         – For patients with uncomplicated symptomatic COVID-19, we typically restart antirheumatic medications within 7 to 14 days of symptom resolution. As examples, such patients include those with mild or no pulmonary symptoms who have been treated in the ambulatory setting or by self-quarantine. For patients who remain asymptomatic after infection but have a positive PCR or antigen test result for SARS-CoV-2, we may delay restarting antirheumatic medications 10 to 17 days after the test result. As above, the timing should be individualized according to vaccination status, previous receipt of monoclonal antibodies and other COVID-19-specific therapies, and rheumatologic disease management considerations. Patients with cancer who have been treated with B cell-depleting agents and develop COVID-19 infection show prolonged PCR positivity that correlates with culturable virus [
         <a href="#rid106">
          106
         </a>
         ], and therefore the window of holding antirheumatic agents may need to be longer in that group with impaired humoral immunity to avoid viral persistence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe COVID-19
         </strong>
         – Decisions regarding the timing of reinitiating rheumatologic disease therapies in patients recovering from more severe COVID-19-related illness should be individualized based upon the severity and organ systems affected, the clinical urgency of resuming antirheumatic drug therapy, and shared decision-making that considers the relative risks and benefits of the relevant treatments in the context of the patient's infection and its related complications.
        </p>
        <p>
        </p>
        <p>
         Our approach is consistent with the guidelines of the ACR [
         <a href="#rid88">
          88
         </a>
         ], the limited data that relate to this issue, and observations regarding the course of the infection (see
         <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">
          "COVID-19: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis"
         </a>
         ). In a small observational study of nine patients, seroconversion was detected in all patients after two weeks and viral loads progressively decreased; despite detection of virus by PCR, live virus was unable to be isolated after eight days [
         <a href="#rid107">
          107
         </a>
         ]. Further information regarding how long patients with rheumatologic disease harbor live virus and remain infectious is needed.
        </p>
        <p>
         The role for either direct detection of SARS-CoV-2 (eg, by PCR) or for antiviral antibody testing for deciding when medications can be resumed following infection is uncertain. Virus has been detected in selected patients by PCR for periods approaching 30 days [
         <a href="#rid107">
          107
         </a>
         ]. As alluded to above, some reports suggest prolonged SARS-CoV-2 shedding may be more common among immunosuppressed hosts.
        </p>
        <p>
         The management of COVID-19 is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">
          "COVID-19: Evaluation of adults with acute illness in the outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3572058786">
         <span class="h1">
          MANAGEMENT CONSIDERATIONS FOR PATIENTS IN THE ABSENCE OF INFECTION OR KNOWN EXPOSURE
         </span>
        </p>
        <p class="headingAnchor" id="H2613778915">
         <span class="h2">
          General principles
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with rheumatologic diseases should be practicing the widely recommended prevention strategies that are focused on mitigating infection risk. This includes adopting practices such as optimal hand hygiene, physical distancing, and wearing a mask in public when adequate physical distancing is not possible. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients with newly diagnosed, stable, or active disease, management generally does not differ from usual treatment approaches in the absence of COVID-19. Modifications of the treatment regimen (eg, use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) should be individualized and influenced by disease severity and the presumed effectiveness and safety of available treatment alternatives.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3432603820">
         <span class="h2">
          Modifications to routine rheumatologic care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Modifications to routine rheumatologic care that minimize risk of exposure to COVID-19 when necessary (eg, during periods of increased prevalence and risk) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimal use of telehealth visits, ideally with video. Descriptions of approaches to examination of the musculoskeletal system during a telemedicine visit have been reported for the shoulder, hips, and knees [
         <a href="#rid108">
          108,109
         </a>
         ]; the cervical and lumbar spine [
         <a href="#rid108">
          108
         </a>
         ]; the elbows [
         <a href="#rid109">
          109
         </a>
         ]; the ankles [
         <a href="#rid108">
          108,110
         </a>
         ]; and the feet [
         <a href="#rid110">
          110
         </a>
         ]. Additionally, strategies for assessment of disease activity have also been described [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some rheumatologists and patients have found telehealth to be useful and effective [
         <a href="#rid112">
          112
         </a>
         ]. However, there are some disadvantages to depending upon this approach. While some clinicians have used telehealth to facilitate ongoing care, many patients lack access to the required technology [
         <a href="#rid113">
          113,114
         </a>
         ]. Less than half of rheumatologists in one survey felt they were able to provide efficient care with telehealth, and it often required more time than an in-person visit [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1434702186">
         <span class="h2">
          COVID-19 vaccination while on immunosuppressive therapy
         </span>
        </p>
        <p class="headingAnchor" id="H1412825303">
         <span class="h3">
          Indications for vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         For nearly all eligible individuals with systemic rheumatic diseases, we recommend COVID-19 vaccination, consistent with age restrictions of local regulatory authorities. The safety of COVID-19 vaccination in patients with inflammatory rheumatic diseases appears to be similar to that in patients with noninflammatory rheumatic diseases [
         <a href="#rid116">
          116,117
         </a>
         ]. When possible, vaccinations should be administered prior to the initiation of immunosuppression [
         <a href="#rid57">
          57
         </a>
         ]. Patients with systemic rheumatic diseases who are receiving any immunosuppressive or immunomodulatory therapy are also generally considered to be among those immunosuppressed patients who are appropriate candidates for additional vaccine doses (extra primary series dose and boosters) following the usual primary series  (
         <a class="graphic graphic_figure graphicRef138339" href="/z/d/graphic/138339.html" rel="external">
          figure 1
         </a>
         ). In a large population-based study, vaccine effectiveness against severe outcomes (hospitalization or death due to COVID-19) after two doses was between 92 and 97 percent for patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, or inflammatory bowel disease [
         <a href="#rid118">
          118
         </a>
         ]. The COVID-19 vaccine schedule for immunocompromised patients is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Immunocompromised individuals'
         </a>
         .)
        </p>
        <p>
         These immunosuppressive or immunomodulatory therapies include
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         (SSZ),
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         (LEF),
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA), CYC, tumor necrosis factor (TNF) inhibitors, interleukin (IL) 6 inhibitors, IL-1 inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors,
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         , oral calcineurin inhibitors, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG),
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX),
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , glucocorticoids,
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         . Nonsteroidal antiinflammatory drugs (NSAIDs) and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         (HCQ) are not considered to be immunosuppressive and therefore are not indications for additional vaccine doses.
        </p>
        <p>
         The use of one or more additional vaccine doses following the primary series in immunocompromised individuals is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Immunocompromised individuals'
         </a>
         .)
        </p>
        <p>
         Following COVID-19 vaccination, patients should continue to follow all public health guidelines regarding physical distancing and other preventive measures.
        </p>
        <p>
         We do not routinely order any laboratory testing (eg, antibody tests for IgM and/or IgG to spike or nucleocapsid proteins) to assess immunity to SARS-CoV-2 post-vaccination or to assess the need for vaccination in a yet-unvaccinated person. We do not know the levels of anti-SARS-CoV-2 spike antibodies that protect against COVID-19 infection, hospitalization due to severe COVID-19 infection, and death from COVID-19 infection (ie, that convey seroprotection); therefore, the clinical utility of these test results has not been established in this setting.
        </p>
        <p class="headingAnchor" id="H3882960080">
         <span class="h3">
          Coordinating vaccine administration with immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For some patients taking specific immunomodulatory therapies, we suggest modifications to either the immunomodulatory medication or vaccine timing. Adjustments to medication regimens should be individualized with specific attention to the severity of the disease activity, as some patients with poorly controlled or severe disease may not tolerate a temporary medication interruption.
        </p>
        <p>
         Although most patients with systemic rheumatic diseases are able to develop adequate protection in response to vaccinations, the immune response may be blunted in patients receiving certain immunomodulatory therapies [
         <a href="#rid31">
          31-37
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Immunocompromised individuals'
         </a>
         ). In particular, B lymphocyte-depleting agents (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) and other medications that affect lymphocytes (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , CYC, AZA, and MTX) may impair an appropriate antibody response to the messenger ribonucleic acid (mRNA) vaccines [
         <a href="#rid31">
          31-34,55,119-122
         </a>
         ]. However, antigen-specific CD4 and CD8 cellular responses may be induced by mRNA vaccines despite reduced antibody responses [
         <a href="#rid123">
          123-126
         </a>
         ].
        </p>
        <p>
         Our approach to vaccine dosing and timing in patients requiring immunomodulatory therapy is consistent with that of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rheumatology.org%2FPortals%2F0%2FFiles%2FCOVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf&amp;token=lWG9UMWByiMTKRwcXbZklZjDhvvcYzsk4UbCJueW%2BYJe3zlUvOcnBCoGSp%2BOYLEY%2BNJ%2BNz9Qwlktt5z%2BeVs2I4nQGIBzwDGIOLrvhOKWqLD%2FZ16q0SfBzkw9MDfo%2BRzO4s8bQLo6Nr8BCx%2F92IH35Q%3D%3D&amp;TOPIC_ID=127933" target="_blank">
          American College of Rheumatology (ACR) COVID-19 Vaccine Clinical Guidance Task Force
         </a>
         and is as follows [
         <a href="#rid127">
          127-132
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abatacept
         </strong>
         <strong>
          (intravenous)
         </strong>
         – We suggest timing the vaccine administration so that it occurs one week prior to the next dose of intravenous
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abatacept
         </strong>
         <strong>
          (subcutaneous)
         </strong>
         – We suggest holding subcutaneous
         <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">
          abatacept
         </a>
         for one to two weeks (as disease activity allows) after each vaccine dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acetaminophen
         </strong>
         <strong>
          , NSAIDs
         </strong>
         – We suggest holding
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         and NSAIDs for 24 hours prior to each vaccine dose, assuming that the disease is stable. There are no restrictions on use after vaccination once symptoms develop.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Belimumab
         </strong>
         <strong>
          (subcutaneous)
         </strong>
         – We suggest holding
         <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">
          belimumab
         </a>
         for one to two weeks (as disease activity allows) after each vaccine dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TNF inhibitors, anti-IL-6 receptor inhibitor, IL-1 inhibitors, IL-17 inhibitors, IL-12/23, and other cytokine inhibitors
         </strong>
         – These medications may be continued without modifications to therapy. However, some experts prefer to hold these medications (as disease activity allows) for one to two weeks after each vaccine dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclophosphamide
         </strong>
         <strong>
          (intravenous)
         </strong>
         – We suggest administering intravenous CYC so that it will occur approximately one week after each vaccine dose, when feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydroxychloroquine
         </strong>
         <strong>
          , glucocorticoids, and
         </strong>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         – These medications may be continued without modifications to therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         <strong>
          or other anti-CD20 B cell-depleting agents
         </strong>
         – We suggest initiating the vaccine series approximately four weeks prior to the next scheduled
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         cycle, assuming the patient's COVID-19 exposure risk can be reasonably mitigated by preventive health measures. We also suggest delaying rituximab two to four weeks after the second vaccine dose. Subsequent vaccine doses may be given two to four weeks before the next anticipated rituximab dose. Some clinicians use CD19 B cell counts as a guide for vaccine timing and subsequent rituximab dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An observational study including 123 patients with systemic rheumatic diseases found that patients receiving
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         were less likely to develop an antibody response after the first dose of SARS-CoV-2 mRNA vaccine compared with other immunomodulatory agents [
         <a href="#rid32">
          32
         </a>
         ]. A second dose of a SARS-CoV-2 vaccine had little impact on the seroconversion rate in patients receiving rituximab [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective cohort study comparing the serologic response to the mRNA vaccine of 87 patients on
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         with that of 1096 healthy controls, 22 percent of patients versus 98 percent of healthy controls demonstrated a serologic response after two doses [
         <a href="#rid122">
          122
         </a>
         ]. The time since the last rituximab infusion was associated with serologic response (median 267 days in responders versus 107 days in nonresponders). After 2 vaccine doses, 53 percent of patients on rituximab had a CD4 T cell response and 74 percent had a CD8 T cell response. Among the patients on rituximab who received a third vaccine dose, 16 percent had a serologic response and 100 percent demonstrated T cell responses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other conventional and targeted immunosuppressive medications
         </strong>
         (eg,
         <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">
          apremilast
         </a>
         ; AZA; calcineurin inhibitors; CYC [oral]; LEF; MTX; Janus kinase [JAK] inhibitors [
         <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">
          baricitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">
          upadacitinib
         </a>
         ];
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ; SSZ) – We suggest holding each medication for one to two weeks after vaccine dose. If possible, mycophenolate should also be held the week before the vaccine is administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An observational study including 123 patients with systemic rheumatic diseases found that patients receiving
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         were less likely to develop an antibody response after the first dose of SARS-CoV-2 mRNA vaccine compared with other immunomodulatory agents [
         <a href="#rid32">
          32
         </a>
         ]. A second dose of a SARS-CoV-2 vaccine improved the seroconversion rate in patients treated with mycophenolate [
         <a href="#rid31">
          31
         </a>
         ]. Another observational study of patients with systemic lupus erythematosus (SLE) receiving an mRNA COVID-19 vaccine found that holding mycophenolate for a week after vaccination increased SARS-CoV-2 antibody IgG levels without an increase in SLE flares compared with continuing mycophenolate [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one series involving two cohorts (from the United States and Germany) with a total of 82 patients with immune-mediated inflammatory diseases who received two doses of an mRNA vaccine, humoral responses were judged as inadequate more often in patients receiving background MTX compared with those not taking MTX and healthy controls (62 versus 92 and 98 percent, respectively) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several randomized trials have suggested patients who temporarily hold MTX have a better antibody response compared with those who continue therapy [
         <a href="#rid134">
          134,135
         </a>
         ]. As an example, in a randomized trial of 178 patients with either rheumatoid arthritis or psoriatic arthritis, holding one dose of MTX following the second dose of the vaccine in the initial series was associated with an increase in the median post-vaccination antibody titers when compared with giving MTX as scheduled (2553 versus 990 international units) and did not increase the risk of disease flare [
         <a href="#rid134">
          134
         </a>
         ]. In a post-hoc analysis, holding MTX following each vaccination in the initial series did not further augment the antibody response.
        </p>
        <p>
        </p>
        <p>
         This approach is largely based on expert opinion, evidence extrapolated from the immunologic effects of the individual medications as they relate to other vaccines and vaccine types, and observational data among patients who have received a SARS-CoV-2 mRNA vaccine. The efficacy of this approach remains to be established.
        </p>
        <p class="headingAnchor" id="H1731573803">
         <span class="h3">
          Additional considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been hypothesized that patients who have had SARS-CoV-2 infection complicated by multisystem inflammatory syndrome (MIS) may be at risk for a dysregulated response after vaccination. Considerations regarding vaccination in patients with a history of MIS are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'History of SARS-CoV-2 infection'
         </a>
         .)
        </p>
        <p>
         It remains uncertain whether the vaccines for COVID-19 may provoke a flare of an underlying systemic rheumatic disease as a result of immune activation or secondary to nonspecific adjuvant effect. Limited data have suggested a low incidence rate of a possible disease flare following vaccination [
         <a href="#rid116">
          116,136-138
         </a>
         ]. In a large cohort including patients with inflammatory systemic rheumatic diseases, approximately 4 percent of patients experienced a disease flare [
         <a href="#rid116">
          116
         </a>
         ]. The mean time to flare following vaccination was six days. Adverse effects associated with COVID-19 vaccines are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Expected adverse effects and their management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Rare but serious associated events'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2066444881">
         <span class="h2">
          Pre-exposure prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with rheumatologic diseases who are moderately to severely immunocompromised and who may not have mounted an adequate immune response to the COVID-19 vaccine may be appropriate candidates for pre-exposure prophylaxis monoclonal antibody therapy. However, there are currently no options approved by the US Food and Drug Administration (FDA) for pre-exposure prophylaxis because most circulating variants are resistant or have reduced susceptibility to these therapies. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1111935894">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited evidence identifying risk factors for poor outcomes with COVID-19 infection unique to patients with rheumatologic disease. There is also limited evidence of adverse rheumatologic disease outcomes following infection other than the short-term risk of increased disease activity due to temporary drug discontinuation. The use of vaccination, pre-exposure prophylaxis, and COVID-19-specific therapies are likely to benefit patients with rheumatologic diseases, but available data are limited. (See
         <a class="local">
          'Disease- and comorbidity-related risks'
         </a>
         above and
         <a class="local">
          'Risks associated with rheumatologic disease therapies'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2898155487">
         <span class="h1">
          DISEASE REGISTRIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several registries have enrolled patients with systemic rheumatic diseases to improve the understanding of the impact of SARS-CoV-2 virus infection on this patient population. More information can be found on the following websites:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frheum-covid.org%2F&amp;token=irwEsZGZTBUaoOJLaj5vsmbju8uywDm3hSpsfPvPF1qvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=127933" target="_blank">
          COVID-19 Global Rheumatology Alliance registry
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.eular.org%2Feular-covid-19-registry&amp;token=%2B0rEyHQ1T7gRoXXx698zAiKnn5%2BXjjVF6anpsoY8z%2BKs8%2BIMe65b8UR7W1Z1D0BUfjMOsTbR4L6rLeQW%2FjG5Ew%3D%3D&amp;TOPIC_ID=127933" target="_blank">
          The EULAR – COVID-19 registry for rheumatologists and other clinicians
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1801266298">
         <span class="h1">
          RESOURCES FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to resources with information about COVID-19 for patients with rheumatologic diseases from select rheumatology society and government-sponsored guidelines are presented separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/130984.html" rel="external">
          "Society guideline links: COVID-19 – Rheumatology care", section on 'Resources for patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2723701254">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">
          "Society guideline links: COVID-19 – Index of guideline topics"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/130984.html" rel="external">
          "Society guideline links: COVID-19 – Rheumatology care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H578864918">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">
          "Patient education: COVID-19 overview (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">
          "Patient education: COVID-19 vaccines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H473188180">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of COVID-19 infection
         </strong>
         – The presence of a rheumatologic disease alone may be associated with an increased risk for developing COVID-19 with more adverse outcomes, although the evidence is mixed. Additionally, patients with various rheumatologic diseases have a higher prevalence of several comorbidities such as advanced age, chronic pulmonary and kidney disease, heart disease, hypertension, obesity, and diabetes, which, in turn, are risk factors for severe illness with COVID-19. (See
         <a class="local">
          'Disease- and comorbidity-related risks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some observational data suggest that
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         use is associated with an increased risk of more severe COVID-19 infection. (See
         <a class="local">
          'Risks associated with rheumatologic disease therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The clinical features of COVID-19 among patients with systemic rheumatic diseases are variable and are not known to be different from those of patients without these underlying diseases. However, a variety of rheumatologic diseases may have clinical features that can mimic or be mimicked by COVID-19, such as malaise, myalgias, and fatigue. For patients with an existing diagnosis of a rheumatologic disease, the clinician may need to distinguish signs and symptoms of a disease flare from those of possible COVID-19 infection; therefore, a high level of suspicion of COVID-19 should be maintained where it is prevalent. (See
         <a class="local">
          'Clinical presentation of the infection in patients with rheumatologic disease'
         </a>
         above and
         <a class="local">
          'Features of rheumatologic disease that can mimic or be mimicked by COVID-19'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication management following exposure
         </strong>
         – Adjustments to medication regimens in patients thought to be recently exposed to the SARS-CoV-2 virus should be individualized, with considerations regarding vaccination status, suspected or known individual's vaccine response, patient's immunosuppressive regimen (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         use) and other risk factors, and access to COVID-19-specific therapies. (See
         <a class="local">
          'Medication management in patients following exposure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication management with infection
         </strong>
         – Adjustments to medication regimens in patients with documented or presumptive COVID-19 should be individualized with specific attention to the severity of the infection. Our general approach is as follows (see
         <a class="local">
          'Medication management with documented or presumptive COVID-19'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients with documented or presumptive COVID-19, we suggest temporarily holding
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         (HCQ)/
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         (CQ),
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         (SSZ),
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (MTX),
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         (LEF), immunosuppressants (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         [AZA],
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [CYC]), biologic agents (eg, anti-tumor necrosis factor [TNF] inhibitors, interleukin [IL] 6 receptor inhibitors), and Janus kinase (JAK) inhibitors during the period of active infection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, in cases where patients have active or organ-threating rheumatologic disease, continuation of their immunosuppressive therapy may be required based upon an individualized assessment. The decision to continue these agents should be made in close consultation with the experts in rheumatology, infectious disease, and critical care involved in the management of the patient's acute illnesses. Another exception to discontinuation of a particular agent may be for selected patients in whom an antirheumatic therapeutic also has value for the treatment of features of COVID-19. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Specific treatments'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients receiving glucocorticoids should maintain the prescribed dose to avoid acute rheumatologic disease flare and the complications of adrenal insufficiency associated with abrupt discontinuation of this medication. The use of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         for the treatment of severe COVID-19 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">
          "COVID-19: Management of the intubated adult", section on 'Use of glucocorticoids for non-COVID-19 reasons'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults", section on 'Patients with oxygen requirement/severe disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postinfection rheumatologic disease management
         </strong>
         – The timing for resumption of antirheumatic drug therapy depends largely upon the severity and characteristics of the infection in a given patient and the time since exposure to the infection or onset of symptoms. The rheumatologic disease indications and urgency of reinstitution of therapy may also influence timing. For asymptomatic patients with positive testing for the virus, we usually resume therapy 10 to 17 days after positive testing; for patients with symptomatic but uncomplicated disease, we wait until 7 to 14 days after symptom resolution; however, the specific date to resume treatment should be individualized according to vaccination status and/or previous receipt of monoclonal antibodies and other COVID-19-specific therapies. For patients with more severe disease, an individualized approach is required. (See
         <a class="local">
          'Postinfection management/resumption of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients
         </strong>
         <strong>
          without known exposure
         </strong>
         – The medication management of patients with newly diagnosed, stable, or active rheumatologic disease who are not known to have infection with or without exposure to SARS-CoV-2 generally does not differ from usual treatment approaches in the absence of COVID-19. We initiate or continue all medications indicated for the management of the patient's systemic rheumatic disease. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Modifications to routine rheumatologic care that minimize risk of exposure to COVID-19 when possible include optimal use of telehealth visits, decreased frequency of routine laboratory surveillance when associated risk is deemed to be low, and the use of lower-volume laboratories offsite from larger health care facilities. (See
         <a class="local">
          'Modifications to routine rheumatologic care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COVID-19 vaccination
         </strong>
         – For eligible individuals with systemic rheumatic diseases, we recommend COVID-19 vaccination to reduce the risk of serious illness, hospitalization, and death (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Patients with systemic rheumatic diseases who are receiving any immunosuppressive or immunomodulatory therapy are also generally considered to be among those immunosuppressed patients who are appropriate candidates for additional vaccine doses following the primary series  (
         <a class="graphic graphic_figure graphicRef138339" href="/z/d/graphic/138339.html" rel="external">
          figure 1
         </a>
         ). The COVID-19 vaccine schedule for immunocompromised patients is discussed in detail separately. (See
         <a class="local">
          'Indications for vaccination'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Immunocompromised individuals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of vaccination
         </strong>
         – For patients taking certain immunomodulatory therapies, we suggest holding such agents (typically for one week) after vaccination if disease activity is adequately controlled (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The immune response to the SARS-CoV-2 vaccines in patients receiving immunomodulatory therapies may be blunted compared with the general population. However, adjustments to medication regimens should be individualized with specific attention to the severity of the disease activity. This general approach applies to any dose of vaccine, whether part of the primary series or a booster dose. Details regarding the specific immunomodulatory therapies are presented above. (See
         <a class="local">
          'Coordinating vaccine administration with immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pre-exposure prophylaxis
         </strong>
         – Patients with rheumatologic diseases who are moderately to severely immunocompromised and who may not have mounted an adequate immune response to the COVID-19 vaccine may be appropriate candidates for pre-exposure prophylaxis monoclonal antibody therapy. However, there are currently no options approved by the US Food and Drug Administration (FDA) for pre-exposure prophylaxis because most circulating variants are resistant or have reduced susceptibility to these therapies. (See
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – There is limited evidence identifying risk factors for poor outcomes with COVID-19 infection unique to patients with rheumatologic disease and limited evidence of adverse rheumatologic disease outcomes following infection itself. The use of vaccination, pre-exposure prophylaxis, and COVID-19-specific therapies is likely to benefit patients with rheumatologic diseases, but further studies are needed. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2154550006">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Ted R Mikuls, MD, MSPH and Ellen M Gravallese, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020; 2:e557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Y, Chen Z, Wang Y, et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study. Ann Rheum Dis 2020; 79:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 2020; 79:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatol 2020; 2:e549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasseli R, Mueller-Ladner U, Hoyer BF, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           England BR, Roul P, Yang Y, et al. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol 2021; 73:2179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Silva KM, Jorge A, Cohen A, et al. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 2021; 73:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eder L, Croxford R, Drucker AM, et al. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. J Rheumatol 2022; 49:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol 2022; 4:e490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eder L, Croxford R, Drucker AM, et al. Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing. Arthritis Care Res (Hoboken) 2023; 75:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gartshteyn Y, Askanase AD, Schmidt NM, et al. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol 2020; 2:e452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugarte-Gil MF, Alarcón GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis 2022; 81:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugarte-Gil MF, Alarcón GS, Seet AM, et al. Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance. Arthritis Care Res (Hoboken) 2023; 75:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie D, Choi HK, Dalbeth N, et al. Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study. Arthritis Rheumatol 2023; 75:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichile T, Petri M. Prevention and management of co-morbidities in SLE. Presse Med 2014; 43:e187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: Review and update. Clin Immunol 2020; 214:108397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burner TW, Rosenthal AK. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009; 21:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Queiro R, Lorenzo A, Tejón P, et al. Obesity in psoriatic arthritis: Comparative prevalence and associated factors. Medicine (Baltimore) 2019; 98:e16400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol 2020; 32:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med 2020; 383:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, et al. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. J Rheumatol 2021; 48:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatol 2021; 3:e166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford) 2021; 60:SI59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruddy JA, Connolly CM, Boyarsky BJ, et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly CM, Boyarsky BJ, Ruddy JA, et al. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. Ann Intern Med 2021; 174:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021; 80:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021; 80:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis 2021; 80:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med 2021; 27:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowalski EN, Wang X, Patel NJ, et al. Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study. Semin Arthritis Rheum 2023; 63:152286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conticini E, Bargagli E, Bardelli M, et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis 2021; 80:e14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 2020; 33:e13475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moiseev S, Avdeev S, Brovko M, et al. Rheumatic diseases in intensive care unit patients with COVID-19. Ann Rheum Dis 2021; 80:e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis 2020; 79:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye C, Cai S, Shen G, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 2020; 79:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fallet B, Kyburz D, Walker UA. Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. Arthritis Rheumatol 2020; 72:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis 2021; 80:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briggs FBS, Gianfrancesco MA, George MF. More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med 2020; 383:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naldi L, Cazzaniga S. More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med 2020; 383:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyrin-Biroulet L, Danese S. More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med 2020; 383:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haberman RH, Adhikari S, Scher JU. More on Covid-19 in Immune-Mediated Inflammatory Diseases. Reply. N Engl J Med 2020; 383:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izadi Z, Brenner EJ, Mahil SK, et al. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open 2021; 4:e2129639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021; 3:e419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgener S, Rochat P, Dollenmaier G, et al. Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review. Case Rep Infect Dis 2022; 2022:8712424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liew J, Gianfrancesco M, Harrison C, et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviv R, Weber A, Anzum T, et al. Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy. J Infect Dis 2021; 224:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020; 79:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2021; 80:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenavandeh S, Sefidbakht S, Iranpour P, et al. COVID-19 and granulomatosis with polyangiitis (GPA): a diagnostic challenge. Rheumatology (Oxford) 2020; 59:2170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol 2021; 3:e224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kant S, Raman G, Damera P, et al. Characteristics and Outcomes of COVID-19 in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney Int Rep 2021; 6:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu TY, D'Silva KM, Patel NJ, et al. Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol 2021; 3:e402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baimukhamedov C, Barskova T, Matucci-Cerinic M. Arthritis after SARS-CoV-2 infection. Lancet Rheumatol 2021; 3:e324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open 2020; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talarico R, Stagnaro C, Ferro F, et al. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol 2020; 2:e518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-González MD, Peral-Garrido ML, Calabuig I, et al. Case series of acute arthritis during COVID-19 admission. Ann Rheum Dis 2021; 80:e58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fineschi S. Case Report: Systemic Sclerosis After Covid-19 Infection. Front Immunol 2021; 12:686699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uppal NN, Kello N, Shah HH, et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5:2079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moeinzadeh F, Dezfouli M, Naimi A, et al. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report. Iran J Kidney Dis 2020; 14:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bamidis AD, Koehler P, di Cristanziano V, et al. First manifestation of adult-onset Still's disease after COVID-19. Lancet Rheumatol 2021; 3:e319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19. Ann Intern Med 2020; 173:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allez M, Denis B, Bouaziz JD, et al. COVID-19-Related IgA Vasculitis. Arthritis Rheumatol 2020; 72:1952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaigany S, Gnirke M, Guttmann A, et al. An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19. Lancet 2020; 396:e8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cogan E, Foulon P, Cappeliez O, et al. Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report. Front Med (Lausanne) 2020; 7:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones I, Bell LCK, Manson JJ, et al. An adult presentation consistent with PIMS-TS. Lancet Rheumatol 2020; 2:e520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokolovsky S, Soni P, Hoffman T, et al. COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult. Am J Emerg Med 2021; 39:253.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davogustto GE, Clark DE, Hardison E, et al. Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection. JAMA Netw Open 2021; 4:e2110323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open 2021; 4:e2126456.
          </a>
         </li>
         <li class="breakAll">
          https://www.cdc.gov/mis/mis-a/hcp.html.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA 2021; 325:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez L, Burgner D, Glover C, et al. Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant. Lancet Reg Health West Pac 2022; 27:100604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy N, Koppel JH, Kaplan O, et al. Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel. JAMA 2022; 327:2452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holm M, Espenhain L, Glenthøj J, et al. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave. JAMA Pediatr 2022; 176:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygaard U, Holm M, Hartling UB, et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health 2022; 6:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Recher M, Hubert H, et al. Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France. JAMA 2022; 327:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep 2022; 71:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol 2021; 73:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulze-Koops H, Specker C, Iking-Konert C, et al. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis 2020; 79:840.
          </a>
         </li>
         <li class="breakAll">
          COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders. NICE guideline [NG167] Published date: 03 April 2020   Last updated: 30 April 2020. https://www.nice.org.uk/guidance/ng167 (Accessed on May 06, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matucci-Cerinic M, Bruni C, Allanore Y, et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 2020; 79:724.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (Accessed on March 19, 2020).
         </li>
         <li class="breakAll">
          WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 (Accessed on April 21, 2020).
         </li>
         <li class="breakAll">
          National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on October 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis 2021; 80:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drake TM, Fairfield CJ, Pius R, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol 2021; 3:e498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis. J Clin Med 2018; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez J, Roustit M, Lepelley M, et al. Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. Ann Intern Med 2021; 174:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol 2017; 29:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020; 79:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winthrop KL, Curtis JR, Lindsey S, et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol 2017; 69:1960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med 2020; 383:2586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskowski ER, Johnson SE, Shelerud RA, et al. The Telemedicine Musculoskeletal Examination. Mayo Clin Proc 2020; 95:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka MJ, Oh LS, Martin SD, Berkson EM. Telemedicine in the Era of COVID-19: The Virtual Orthopaedic Examination. J Bone Joint Surg Am 2020; 102:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eble SK, Hansen OB, Ellis SJ, Drakos MC. The Virtual Foot and Ankle Physical Examination. Foot Ankle Int 2020; 41:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           England BR, Barber CEH, Bergman M, et al. Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. Arthritis Care Res (Hoboken) 2021; 73:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferucci ED, Holck P, Day GM, et al. Factors Associated With Use of Telemedicine for Follow-up of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2020; 72:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta B, Jannat-Khah D, Fontana MA, et al. Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey. RMD Open 2020; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muehlensiepen F, Knitza J, Marquardt W, et al. Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study. J Med Internet Res 2021; 23:e23742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh JA, Richards JS, Chang E, et al. Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists. Arthritis Care Res (Hoboken) 2021; 73:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis 2022; 81:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen P, Ravichandran N, Nune A, et al. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (Oxford) 2022; 62:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Widdifield J, Kwong JC, Chen S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol 2022; 4:e430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deepak P, Kim W, Paley MA, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med 2021; 174:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021; 80:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 2021; 3:e789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 2022; 4:e177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 2021; 27:1990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021; 80:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitoun S, Henry J, Desjardins D, et al. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases. Arthritis Rheumatol 2022; 74:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, et al. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis Rheumatol 2022; 74:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol 2021; 73:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. Arthritis Rheumatol 2021; 73:e30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol 2021; 73:e60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis Rheumatol 2022; 74:e21.
          </a>
         </li>
         <li class="breakAll">
          https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf (Accessed on February 07, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis Rheumatol 2023; 75:E1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petri M, Joyce D, Haag K, et al. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response. Arthritis Care Res (Hoboken) 2023; 75:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skaria TG, Sreeprakash A, Umesh R, et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatol 2022; 4:e755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med 2022; 10:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terracina KA, Tan FK. Flare of rheumatoid arthritis after COVID-19 vaccination. Lancet Rheumatol 2021; 3:e469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 2022; 24:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fragoulis GE, Bournia VK, Mavrea E, et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. Rheumatol Int 2022; 42:31.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 127933 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32796045" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32838309" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32471903" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32546598" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32532753" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32838307" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33479021" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33955209" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305544" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35105713" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35698725" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34486829" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32835249" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : COVID-19 and systemic lupus erythematosus: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35172961" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36239292" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36082457" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Gout and Excess Risk of Severe SARS-CoV-2 Infection Among Vaccinated Individuals: A General Population Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915155" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Co-morbidity in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26282082" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cardiovascular comorbidity in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24855047" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevention and management of co-morbidities in SLE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32229290" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Comorbidities associated with psoriatic arthritis: Review and update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19077719" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diabetes and rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31305449" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Obesity in psoriatic arthritis: Comparative prevalence and associated factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18467370" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hypertension in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32675715" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33504483" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32348641" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33722949" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33521657" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32640463" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Factors associated with COVID-19-related death using OpenSAFELY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33369663" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34031032" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33757968" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34029488" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34035003" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34127481" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34144967" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34331051" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37913612" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32241793" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32414804" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32356577" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32434823" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Rheumatic diseases in intensive care unit patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32457048" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32444415" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32458534" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32769150" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34049860" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32649070" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : More on Covid-19 in Immune-Mediated Inflammatory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32649068" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : More on Covid-19 in Immune-Mediated Inflammatory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32649069" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : More on Covid-19 in Immune-Mediated Inflammatory Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32649071" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : More on Covid-19 in Immune-Mediated Inflammatory Diseases. Reply.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34661663" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33786454" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35251723" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35387864" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33964153" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32503854" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33051220" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32556292" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : COVID-19 and granulomatosis with polyangiitis (GPA): a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33521655" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : COVID-19 vasculitis and novel vasculitis mimics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33521401" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Characteristics and Outcomes of COVID-19 in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33842894" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Incident systemic rheumatic disease following COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33748780" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Arthritis after SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32763956" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Reactive arthritis after COVID-19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32838313" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32471899" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Case series of acute arthritis during COVID-19 admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34262566" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Case Report: Systemic Sclerosis After Covid-19 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32839744" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32361703" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33817663" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : First manifestation of adult-onset Still's disease after COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32726150" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32633104" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : COVID-19-Related IgA Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32659211" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33031361" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32760733" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32838310" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : An adult presentation consistent with PIMS-TS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32631771" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34009351" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34550381" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34550381" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33625505" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36237982" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35588048" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35675054" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35526537" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34928295" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35025852" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33277981" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32345619" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32345619" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32349982" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32349982" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32349982" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32349982" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33478953" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33997800" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117492" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260176" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The risk of hospitalized infection in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17478469" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30583473" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33493009" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28422773" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Infections in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32033941" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32171076" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28845604" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33259154" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32235945" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Virological assessment of hospitalized patients with COVID-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32753146" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The Telemedicine Musculoskeletal Examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32341311" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Telemedicine in the Era of COVID-19: The Virtual Orthopaedic Examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32639852" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The Virtual Foot and Ankle Physical Examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32813284" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31421020" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Factors Associated With Use of Telemedicine for Follow-up of Rheumatoid Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33011680" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33690147" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33058485" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34972811" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35713499" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35441151" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34461029" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34285048" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34514436" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34977602" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34522051" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34362747" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34962357" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34962360" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33728796" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34128356" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34346564" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35474640" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35474640" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36345691" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36714913" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36320825" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35772416" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33817664" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Flare of rheumatoid arthritis after COVID-19 vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35016701" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34739573" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
